Polypathy: searching for etiopathogenetic risks factors

Cover Page

Cite item


The article provides an overview of the literature on the actual problem of diseases - polypathy. The review focuses problematic aspects of comorbid states, the scatter of their definitions, the incidence in different countries according to the international scientific community, the frequency of use of comorbid indices, the influence of racial and ethnicity in polypathies, risk factors for the development of combined diseases both at the level of an individual’s genes and aspects of a person’s lifestyle and the environment, options for their pathogenetic development with examples of nodal chains and their effects (nodules), examples of countries with modified risk factors to reduce mortality according to the approved action plan World Health Organization for the Prevention of Chronic Noncommunicable Diseases. The review focuses on factors contributing to the development of polypathy, in particular connective tissue dysplasia. The problems of diagnosing the external signs of connective tissue dysplasia in comorbid patients according to accepted diagnostic criteria and the frequency of their occurrence abroad and in Russia. An analogy is drawn between the concept of cardiovascular continuum and the development of polypathy in the patient’s body with connective tissue dysplasia of varying severity. There is analyzed the experience of treating patients with comorbid pathology of both the international scientific society of comorbidity (2010) and the Russian recommendations on comorbidity (2016). There is raised the development of COVID-19 in different patients with polypathy in China and other countries.

About the authors

A. V. Fus

Tiraspol Clinical Center for Outpatient Care № 1

Author for correspondence.
Email: fusalla@mail.ru
Tiraspol, The Pridnestrovien Moldavian Republic

G. I. Podolinny

Taras Shevchenko Transnistria State University

Email: fusalla@mail.ru
Tiraspol, The Pridnestrovien Moldavian Republic


  1. Huddon C., Fortin M., Lapointe L. et al. Multimorbidity in medical literature: is it commonly researched? Can. Fam. Physician. 2005; 51: 244–5.
  2. Clinical recommendations. Comorbid pathology in clinical practice. Cardiovascular Therapy and Prevention. 2017; 16 (6). S. 1–152.
  3. Shamurova Yu. Yu. Risk factors for multiple diseases. Kazan medical journal. 2008; 89(3): 286–290.
  4. Feinstein A.R. Pre’therapeutic classification of comorbidity in chronic diseases. Journal Chronic Diseases. 1970; 23(7): 68–455.
  5. Huntley A.L, et al. Measures of Multimorbidity and Morbidity Burden for Use in Primary Care and Community Settings: A Systematic Review and Guide. Annals of Family Medicine. 2012; 10 (2): 41–134.
  6. Garin N, Koyanagi A, Chatterji S. Global Multimorbiditi Patterns. A Cross – Sectional, Population – Based, Multi – Country Study. Journals of Gerontology: Medical Sciences. 2015; 1:1–10.
  7. Sauver J.L. St, Boyd C.M, Grossardt B.R, et al. Risk of developing multimorbidity across all ages in an historical cohort study: differences by sex and ethnicity. BMJ Open. 2015;5(2):1136–1150.
  8. Quinones A.R, Liang J, Bennett J.M, Xu X, Ye W. How Does the Trajectory of Multimorbidity Vary Across Black, White, and Mexican Americans in Middle and Old Age? The journals of gerontology. 2011;66(6):739–749.
  9. Kemmler W, Von Stengel S, Engelke K, Kalender WA. Exercise decreases the risk of metabolic syndrome in elderly females. Med Sci Sports Exerc. 2009 Feb;41(2):297–305.
  10. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians: American geriatrics society expert panel on the care of older adults with multimorbidity. J Am Geriatr Soc. 2012; 60(10): 1–25.
  11. Risk factors. http://www.who.int/ risk factors / (access date 5.01.2020).
  12. Alekseenko S.N., Drobot E.V. Disease Prevention Tutorial. Publishing House Russian Academy of Natural Sciences, 2015.S. 123.
  13. Kalev O.F., Kaleva N.G., Yashin D.A. A single integrated classification of the quality groups of the health of children and adults in the preventive continuum of noncommunicable diseases. 2015. Chelyabinsk.
  14. World Health Organization. http://www.who.int/ncd/(address of September 11, 2019).
  15. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991; 121: 63–1244.
  16. Global status report on noncommunicable diseases 2014. Attaining the nine global noncommunicable diseases targets; a shared responsibility” WHO, 2014.
  17. Puzyrev V.P. A genetic look at the phenomenon of combined human pathology. Medical Genetics. 2008; 9: 3–9.
  18. Becker K.G., Simon R.M., Baiely’Wilson J.E. et al. Clustering of non–major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proceedings of the National Academy of Sciences. 1998; 95: 9979–84.
  19. Zhernakova A., van Diemen C.C., Wiymenga C. Detecting shared pathogenesis from the shared genetics of immune related diseases. Nat. Rev. Genetic. 2009; 10: 43–55.
  20. Puenpatom R.A., Victor T.W. Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analyses of NHANES111 data. Postgard. Med. 2009; 121: 9–20.
  21. Roach H.I., Aigner T. DNA methylation in osteoarthritic chondrocytes: a new molecular target. Osteoarthritis Сartilage. 2007; 15: 128–37.
  22. Glazko V.I. Structural organization of the genome and network theory. News of the Timiryazev Agricultural Academy. 2010; 2: 59–65.
  23. Evin I.A. Complex networks – a new tool for the study of complex systems. Complex systems. 2012; 2: 66–74.
  24. Shirinsky I.V., Kozlov V.A., Shirinsky V.S. The use of statins is a new approach to the treatment of autoimmune diseases. Vestnik RAMS. 2009; 2:26–32.
  25. De Bosscher K. Vanden Berghe W. Mechanisms of antiinflammatory action and immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J. Neuroimmunol. 2000;109:16– 22.
  26. Shirinsky I.V., Shirinsky V.S. Targeting Nuclear Hormone receptors: PPARalpha agonists as Potential Disease–Modifying Drugs for Rheumatoid Arthritis. Int. J. Rhematol. 2011. Vol. 2011. Article ID937843, 8 p.
  27. Shirinsky V.S., Shirinsky I.V. Comorbid diseases are an urgent problem of clinical medicine. Siberian Medical Journal. 2014; 29(1):7–12.
  28. Shirinsky I.V., Shirinsky V.S. Efficacy of simvastatin in plaque psoriases: a pilot study. J. Amer. Academ. Dermathology. 2007; 57: 529–31.
  29. Shirinsky I.V., Zheltova O.I., Solovyeova N.Y. et al. Changes in disease activity, cytokine production and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment. Scand. J. Reumatol. 2009; 38: 23–7.
  30. Shirinsky I.V., Shirinsky V.S. Treatment of erosive osteoarthritis with peroxisome proliferator activated receptor alpha agonist fenofibrate: a pilot study. Rheumatol. Int. 2013. Apr. 26
  31. Schramm A., Franke H., Chowanetz W. Multimorbiditat im Alter. Z Allg Med. 1992;58:234–237.
  32. National recommendations of the Russian Scientific Medical Society of Therapists on the diagnosis, treatment and rehabilitation of patients with connective tissue dysplasia. Medical Bulletin of the North Caucasus. 2016; 11 (1): 2–76.
  33. A.S. Avedisova, M.O. Zhabin, R.G. Akzhigitov, A.A. Gudkova. The problem of multiple somatic and mental pathology. Journal of Neurology and Psychiatry. 2018; 5: 5–13.
  34. Coronavirus (Covid-19). http://health/medicine/koronavirus (дата обращения 14.03.2020).

Copyright (c) 2020 Fus A.V., Podolinny G.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies